The STAR Trial: Evidence for Raloxifene as a Breast Cancer Risk Reduction Agent for Postmenopausal Women

Author： Bevers Therese B.  

Publisher： Cambridge Scholars Publishing in association with GSE Research

ISSN： 1540-1405

Source： Journal of the National Comprehensive Cancer Network (JNCCN), Vol.5, Iss.8, 2007-09, pp. : 817-822

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene

By Ko Seung Sang   Jordan V Craig  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 4, 2011-03 ,pp. : 657-674

Informa Healthcare

Access to resources Recommend Favorite

Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene

By  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1081-1081

Informa Healthcare

Access to resources Recommend Favorite

Raloxifene: a STAR performer in breast cancer prevention?

By  

Inpharma, Vol. 1, Iss. 1546, 2006-01 ,pp. : 7-9

Adis International

Access to resources Recommend Favorite

Raloxifene in breast cancer prevention

By Gennari Luigi   Merlotti Daniela   Paola Vincenzo De   Nuti Ranuccio  

Expert Opinion on Drug Safety, Vol. 7, Iss. 3, 2008-05 ,pp. : 259-270

Informa Healthcare

Access to resources Recommend Favorite

Chemoprevention of Breast Cancer: Implications for Postmenopausal Women

By Fabian C.J.  

Drugs & Aging, Vol. 19, Iss. 1, 2002-01 ,pp. : 43-78

Adis International

Access to resources Recommend Favorite